Pfizer Pipeline

May 10, 2012

Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 10, 2012.

- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot

Pipeline represents progress of R&D programs as of 5/10/12

Included are 64 NMEs, 22 additional indications, plus 1 biosimilar

6 Projects discontinued since last update

Recent Approvals

- **ELELYSO (taliglucerase alpha)** for treatment of adults with a confirmed diagnosis of type 1 Gaucher disease (U.S.)



Pipeline represents progress of R&D programs as of 2/28/12

Included are 70 NMEs plus 20 additional indications

8 Projects discontinued since last update

Recent Approvals

- **Vyndaqel (tafamidis meglumine)** for treatment of treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy (EU)
- **Prevnar 13 Adult** for prevention of pneumococcal pneumonia and invasive disease in adults 50 years of age and older (U.S.)
- **Inlyta (axitinib)** for advanced renal cell carcinoma (U.S.)

Pfizer Pipeline – May 10, 2012

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention (U.S.)	Registration
	Eliquis (apixaban)	Factor Xa Inhibitor	Stroke Prevention in Atrial Fibrillation (U.S./EU)	Registration
	apixaban	Factor Xa Inhibitor	Venous Thromboembolism Prevention (U.S.)	Phase 3
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	PF-04971729		Diabetes Mellitus-Type 2	Phase 2
	PF-04991532		Diabetes Mellitus-Type 2	Phase 2
	RN316 (PF-04950615)		Hypercholesterolemia, Post Acute Coronary Syndrome in Diabetics (Biologic)	Phase 2
	PF-04937319		Diabetes Mellitus-Type 2	Phase 2
	PF-00489791		Diabetic Nephropathy	Phase 2
	CVX 096 (PF-04856883)		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	OAP-189 (PF-05212389)		Diabetes Mellitus-Type 2, Obesity (Biologic)	Phase 1
	PF-03882845		Diabetic Nephropathy	Phase 1
	PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	PF-05190457		Diabetes Mellitus-Type 2	Phase 1

New Molecular Entity

New Indication or Enhancement

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Inflammation and Immunology	tofacitinib (CP-690550)	JAK Inhibitor	Rheumatoid Arthritis (U.S./EU)	Registration
	tofacitinib (CP-690550)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	▶tofacitinib (CP-690550)	JAK Inhibitor	Ulcerative Colitis	Phase 3
	PF-04171327		Rheumatoid Arthritis	Phase 2
	PF-05285401		Ulcerative Colitis (Biologic)	Phase 2
	anrukinzumab (IMA-638)		Ulcerative Colitis (Biologic)	Phase 2
	PF-00547659		Crohn's Disease (Biologic)	Phase 2
	PF-04236921		Crohn's Disease, Lupus, *Rheumatoid Arthritis (Biologic)	Phase 2
	tofacitinib (CP-690550)		Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease	Phase 2
	PF-06473871 (EXC 001)		Dermal Scarring	Phase 2
	PD-360324		Lupus (Biologic)	Phase 1
	▶PF-05280586		Rheumatoid Arthritis (Biosimilar)	Phase 1

New Molecular Entity | New Indication or Enhancement | Biosimilar

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (U.S.)	Registration
	Lyrica	Alpha-2 Delta Ligand	Central Neuropathic Pain due to Spinal Cord Injury (U.S.)	Registration
	Celebrex	COX-2	Chronic Pain (U.S.)	Registration
	Remoxy (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain (U.S.)	Registration
	ALO-02 Oxycodone-naltrexone core (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	bapineuzumab	Beta Amyloid Inhibitor	Alzheimer's Disease (Biologic)	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (Biologic) (On Clinical Hold)	Phase 3
	PF-02545920		Schizophrenia	Phase 2
	Eladur (King)		Chronic Pain (Will return rights to develop and commercialize to DURECT effective August 30, 2012)	Phase 2
	PF-03049423		Stroke Recovery	Phase 2
	tanezumab		Cancer Pain (Biologic)	Phase 2

New Molecular Entity

New Indication or Enhancement

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain (cont'd)	PF-05089771		Acute Pain, *Chronic Pain	Phase 2
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-04958242		Schizophrenia, Sensorineural Hearing Loss	Phase 1
	PF-05212377 (SAM-760)		Alzheimer's Disease	Phase 1
	PF-04427429		Migraine (Biologic)	Phase 1
	PF-05180999		Schizophrenia	Phase 1
	PF-04531083		Severe Chronic Pain	Phase 1

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology	crizotinib	c-MET-ALK Inhibitor	Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer (EU)	Registration
	axitinib	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma after failure of prior systemic treatment (EU)	Registration
	bosutinib	Abl and src-family kinase inhibitor	Previously Treated Chronic Myelogenous Leukemia (U.S.), Chronic Myelogenous Leukemia (EU)	Registration
	dacomitinib (PF-00299804)	pan-HER Inhibitor	Previously Treated Advanced Non-Small Cell Lung Cancer	Phase 3
	Xalkori (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma in treatment-naïve patients	Phase 3
	▶ Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant (Asia only)	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Torisel	FKBP-Rapamycin Associated Protein	Renal Cell Carcinoma 2nd Line (after disease progression on or after Sutent therapy)	Phase 3
	inotuzumab ozogamicin		Aggressive Non-Hodgkin's Lymphoma (Biologic)	Phase 3
	inotuzumab ozogamicin		Indolent Non-Hodgkin's Lymphoma, *Acute Lymphocytic Leukemia (Biologic)	Phase 2
	axitinib		Liver Cancer, Thyroid Cancer	Phase 2

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology (cont'd)	dacomitinib (PF-00299804)		Cancer	Phase 2
	PD-0332991		Cancer	Phase 2
	CVX 060 (PF-04856884)		Renal Cell Carcinoma, *Cancer (Biologic)	Phase 2
	PF-04691502		Endometrial Cancer, *Cancer	Phase 2
	PF-05212384		Endometrial Cancer, *Cancer	Phase 2
	PF-03084014		Cancer	Phase 1
	PF-03446962		Cancer (Biologic)	Phase 1
	PD-0325901		Cancer (in combination with PF-04691502)	Phase 1
	PF-05082566		Cancer (Biologic)	Phase 1
	PF-04605412		Cancer (Biologic)	Phase 1
	PF-04449913		Cancer	Phase 1
Vaccines	ACC-001 (PF-05236806)		Alzheimer's Disease	Phase 2
	MnB rLP2086 (PF-05212366)		Adolescent Meningitis, *Infant Meningitis	Phase 2
	4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)		Staph Aureus	Phase 2

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 10, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus	Taliglucerase alfa	Enzyme Replacement Therapy	Gaucher Disease (Biologic) (EU)	Registration
	Xiapex (EU)	Clostridial Collagenase for Injection	Peyronie's Disease (Biologic) (EU)	Phase 3
	Eraxis/Vfend	Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation	Aspergillosis	Phase 3
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	bazedoxifene-conjugated estrogens	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms	Phase 3
	bosutinib		Autosomal Dominant Polycystic Kidney Disease	Phase 2
	PF-00868554 (filibuvir)		Hepatitis C Virus	Phase 2
	tofacitinib (CP-690550)		Transplant Rejection, Dry Eye	Phase 2
	PH-797804		Chronic Obstructive Pulmonary Disease	Phase 2
	PF-06460031 (GMI-1070)		Vaso-occlusive crisis associated with Sickle Cell Disease	Phase 2
	PNU-100480		Tuberculosis	Phase 2
	RN6G (PF-04382923)		Age-Related Macular Degeneration (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	PF-05280602		Hemophilia (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

Projects Discontinued from Development since February 28, 2012

Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
PF-03654746		Tourette's Syndrome	Phase 2
SBI-087 (PF-05230895)		Rheumatoid Arthritis, *Lupus (Biologic)	Phase 2
PF-04840082		Osteoporosis Treatment and Prevention (Biologic)	Phase 1
PF-04634817		Liver Fibrosis	Phase 1
PF-05297909		Alzheimer's Disease	Phase 1
Vabicaserin (PF-05208769)		Schizophrenia	Phase 1

New Molecular Entity

* Note: Additional indication in Phase 1; development discontinued